A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse

Status Recruiting

Clinical Trial Summary

This is a research study to find out if treatment decision making can be improved for smokers who find it difficult to quit with medications. Everyone who participates in this study will receive free product, either nicotine replacement therapies (patches and lozenges), varenicline, or a harm reduction product (e-cigarette) for a full 12 weeks. Most participants will receive some combination of these treatments, depending on individual response to each. All visits and study assessments will be entirely remote. All treatments will be provided free of charge for the first 12 weeks. After that, the study team will contact the participants 6 months after the first study phone call to complete another survey. The study lasts six months and will involve 8 surveys.

Clinical Trial Description

Treatment seeking smokers across both Alabama and South Carolina (N=544) will be recruited and consented through established online methods and randomized to receive a 4-week course of either varenicline or combination NRT (patch + lozenge), counterbalanced. Using a concrete and measurable indicator of early treatment success (3 days non-smoking), smokers demonstrating early success at 4 week follow-up will continue with another four weeks of same medication, either varenicline or combination NRT. Those who do not demonstrate early success will be randomized to a subsequent 4-week course of either a) continuation of same medication, or b) switch to the other FDA approved option, either varenicline or combination NRT. The same process will repeat at Week 8, wherein treatment responders will continue with their ongoing medication and non-responders will be randomized to a final 4-week course of either a) continuation of same medication or b) switch to an e-cigarette. End of treatment outcomes will be assessed at Week 12 at which time no more product will be offered. Final follow-up at Week 24 will ascertain all primary (cessation) and secondary outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06118502
Study type	Interventional
Source	Medical University of South Carolina
Contact	Tracy T Smith, PhD
Phone	8438725164
Email	smithtra@musc.edu
Status	Recruiting
Phase	N/A
Start date	March 25, 2024
Completion date	March 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Recruiting	`NCT02422914` - Benefits of Tobacco Free Cigarette	N/A
Active, not recruiting	`NCT02629679` - Sports, Education and Consumption of Substances in Adolescents	N/A
Completed	`NCT02385227` - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes	N/A
Completed	`NCT02218281` - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation	N/A
Completed	`NCT01199380` - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms	Phase 2
Completed	`NCT00802919` - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors	Phase 4
Completed	`NCT00756704` - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department	N/A
Completed	`NCT01692353` - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers	N/A
Completed	`NCT01081119` - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth	Phase 2
Completed	`NCT00682474` - School Nurse-Delivered Smoking Cessation Intervention	Phase 2/Phase 3
Completed	`NCT05520775` - Semaglutide for Alcohol Use Disorder	Phase 2
Completed	`NCT03743532` - E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services	N/A
Terminated	`NCT03840694` - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior	N/A
Completed	`NCT06032793` - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.	N/A
Terminated	`NCT03326128` - High Dose Bupropion for Smoking Cessation - Pilot Study	Phase 2
Recruiting	`NCT03218670` - Your Health in On Click	N/A
Completed	`NCT02538042` - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse — ADAPT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms